Salute e Benessere
Syngene launches platform for rapid, enhanced protein production
The new platform accelerates enhanced protein production, enabling quicker preclinical and clinical development as well as product launches, thereby reducing time to market.
said
said .
", said
The new platform streamlines clone selection and enhances operational productivity. It also supports a wide range of biomolecules including monoclonal antibodies, biosimilars, bispecifics, antibody-drug conjugates and other recombinant proteins. This versatility facilitates integration with both perfusion and fed-batch manufacturing processes. A track record in developing multiple monoclonal antibodies with the new technology underscores its effectiveness and reinforces Syngene's ability to provide innovative solutions for its clients. By combining this technology with Syngene's existing capabilities, the Company now offers a full range of end-to-end cell line development options, using the latest technology to deliver tangible benefits to customers.
Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's more than 6000 scientists offer both skills and the capacity to deliver great science, robust data security, and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter , and Bristol-Myers Squibb as well as 2 Mn sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA. For more details, visit www.syngeneintl.com. For the Company's latest Environmental, Social, and Governance (ESG)report, visit https://esgreport.syngeneintl.com/.
(and ExcellGene Inc. USA ) EXCELLGENE SA, located within the beautiful alps of Switzerland , has been leader in cell line generation, cell line development and high yielding manufacturing processes since 2001. It has served hundreds of customers, including some of the largest Pharma and Biotech companies. The company, family-managed and owned, has been at the forefront of cell culture-based technologies for protein production since inception. The more than 300 co-worker publications with >200 citations of these already in 2024 provide evidence of the scientific and technological excellence of the company. For more details, visit www.excellgene.com.
View original content:https://www.prnewswire.co.uk/news-releases/syngene-launches-platform-for-rapid-enhanced-protein-production-302164027.html